Review



anti human igg cat 9200 05 antibodies  (SouthernBiotech)


Bioz Verified Symbol SouthernBiotech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    SouthernBiotech anti human igg cat 9200 05 antibodies
    Anti Human Igg Cat 9200 05 Antibodies, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 93/100, based on 123 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+igg4/Mouse+Anti-Human+IgG4+Fc-HRP/pm42880053-50-11-20
    Average 93 stars, based on 123 article reviews
    anti human igg cat 9200 05 antibodies - by Bioz Stars, 2026-11
    93/100 stars

    Images

    Related Articles

    Staining:

    Article Title: Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors
    Article Snippet: Data analysis was performed using Octet Data Analysis software, version 9.0 (ForteBio), using a 1:1 binding model. Anti-PD-1 antibody binding was also assayed by flow cytometry using Jurkat-Lucia TCR-hPD-1 cells or CHO-K1 and CHO-K1 Fut8 KO cells transfected with plasmids encoding for human PD-1 or chimeric receptors including the extracellular and transmembrane domain of PD-1 linked to the intracellular green fluorescent protein (GenScript) by ExpiFectamine (Thermo Fisher Scientific). .. Cells were washed and stained with 1 μg/ml PE-conjugated anti-human IgG4 (SouthernBiotech) or 3 μg/ml Alexa Fluor 647–conjugated anti-human IgG (Jackson ImmunoResearch) antibodies for 30 min. .. Cells were washed and stained with 1 μg/ml PE-conjugated anti-human IgG4 (SouthernBiotech) or 3 μg/ml Alexa Fluor 647–conjugated anti-human IgG (Jackson ImmunoResearch) antibodies for 30 min.

    Article Title: Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors.
    Article Snippet: Data analysis was performed using Octet Data Analysis software, version 9.0 (ForteBio), using a 1:1 binding model. Anti-PD-1 antibody binding was also assayed by flow cytometry using Jurkat-Lucia TCR-hPD-1 cells or CHO-K1 and CHO-K1 Fut8 KO cells transfected with plasmids encoding for human PD-1 or chimeric receptors including the extracellular and transmembrane domain of PD-1 linked to the intracellular green fluorescent protein (GenScript) by ExpiFectamine (Thermo Fisher Scientific). .. Cells were washed and stained with 1 μg/ml PE-conjugated anti-human IgG4 (SouthernBiotech) or 3 μg/ml Alexa Fluor 647–conjugated anti-human IgG (Jackson ImmunoResearch) antibodies for 30 min. .. Cells were washed and stained with 1 μg/ml PE-conjugated anti-human IgG4 (SouthernBiotech) or 3 μg/ml Alexa Fluor 647–conjugated anti-human IgG (Jackson ImmunoResearch) antibodies for 30 min.

    other:

    Article Title: Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors
    Article Snippet: To confirm activation followed by bead stimulation, cells were stained with BV711-conjugated anti-CD25 antibody (Clone M-A251, Biolegend) at a 1:50 dilution in PBS.

    Incubation:

    Article Title: IgG4 glycosylation contributes to the pathogenesis of IgG4 Hashimoto’s thyroiditis via the complement pathway
    Article Snippet: Briefly, 96-well plates were coated with different antigens (4 μg/mL thyroglobulin; Calbiochem Merck KGaA; 2 μg/mL thyroid peroxidase; Diarect AG). .. Serum samples were diluted and incubated for 30 min. Horseradish peroxidase (HRP)-labeled anti-human IgG4 (HP6025; Southern Biotech; 1:5000 for TgAb IgG4 and 1:1000 for TPOAb IgG4) was added. ..



    Similar Products

    94
    TargetMol human igg4 s228p kappa isotype control
    Human Igg4 S228p Kappa Isotype Control, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+igg4/Human+IgG4+(S228P)+kappa%2C+Isotype+Control/pm42271382-100-61-69
    Average 94 stars, based on 1 article reviews
    human igg4 s228p kappa isotype control - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Sino Biological human igg4 isotype
    Human Igg4 Isotype, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+igg4/Human+IgG4%2C+kappa+Isotype+Control/10__1093_slash_abt_slash_tbag014-62-4-8
    Average 94 stars, based on 1 article reviews
    human igg4 isotype - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    SouthernBiotech anti human igg cat 9200 05 antibodies
    Anti Human Igg Cat 9200 05 Antibodies, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+igg4/Mouse+Anti-Human+IgG4+Fc-HRP/pm42880053-50-11-20
    Average 93 stars, based on 1 article reviews
    anti human igg cat 9200 05 antibodies - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    95
    SouthernBiotech mouse anti human igg4 fc
    Mouse Anti Human Igg4 Fc, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+igg4/Mouse+Anti-Human+IgG4+Fc-PE/10__1038_slash_s41467___026___76882___w-362-68-72
    Average 95 stars, based on 1 article reviews
    mouse anti human igg4 fc - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    SouthernBiotech igg4
    Igg4, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+igg4/Mouse+Anti-Human+IgG4+pFc'-AP/pm42826349-24-17-21
    Average 94 stars, based on 1 article reviews
    igg4 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    InvivoGen human igg4 isotype control antibody
    Human Igg4 Isotype Control Antibody, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+igg4/Anti-%CE%B2-Gal-hIgG4/pm42430880-47-4-12
    Average 94 stars, based on 1 article reviews
    human igg4 isotype control antibody - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    SouthernBiotech abs against human igg4
    Abs Against Human Igg4, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+igg4/Mouse+Anti-Human+IgG4+Fc-Alexa+Fluor+488/pm41721136-733-0-10
    Average 94 stars, based on 1 article reviews
    abs against human igg4 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress human igg4 anti kir2dl1
    Human Igg4 Anti Kir2dl1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+igg4/KIR2DL1%2C+Human/pm42399607-413-5-2
    Average 94 stars, based on 1 article reviews
    human igg4 anti kir2dl1 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress human igg4
    ( A ) Interleukin-2 (IL-2) and interferon gamma (IFN-γ) inhibition in CD3 + cells during allogeneic one-way MLR measured at day 2 and day 5, respectively, treated with 50 nM combination pharmacological inhibitors of TNF/TNFR targets of interest. Monotreatment groups included 50 nM of human <t>IgG1.</t> Cytokine inhibition was calculated as percent reduction from IgG1 control treatment. Ill denotes P <0.05 in student t-test for monotreatments vs. IgG1 control, # denotes P <0.05 in student t-tests for combination treatment groups vs. IgG1 controls and both constituent monotreatments. ( B ) Normalized IL-2 and IFN-γ expression in four promising combinations of TNF/TNFR inhibitors. ( C-D ) Proliferation in CD3 + cells during allogeneic one-way MLR measured at day 5 in the presence of combination pharmacological inhibition of TNF/TNFR targets of interest.* denotes P <0.05 in student t-test. Data from three unique stimulator-responder MLR pairs, mean ± SEM plotted. Large-molecule pharmacological TNF/TNFR inhibitors used: Adalimumab (abbr. Ada, α-TNF), Pateclizumab (α-LTA), Baminercept (abbr. Bam, LTβR decoy), Dapirolizumab (abbr. Dapiro, α-CD40L), Amlitelimab (abbr. Amlite, α-OX40L), CD30Li (α-CD30L), 4-1BB-Fc (4-1BB decoy), Quisovalimab (α-LIGHT), Duvakitug (α-TL1A), and GITRi (α-GITR).
    Human Igg4, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+igg4/Human+IgG4+(S228P)+kappa%2C+Isotype+Control/bio_rxiv__64898__2026__04__27__721101-32-26-33
    Average 94 stars, based on 1 article reviews
    human igg4 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) Interleukin-2 (IL-2) and interferon gamma (IFN-γ) inhibition in CD3 + cells during allogeneic one-way MLR measured at day 2 and day 5, respectively, treated with 50 nM combination pharmacological inhibitors of TNF/TNFR targets of interest. Monotreatment groups included 50 nM of human IgG1. Cytokine inhibition was calculated as percent reduction from IgG1 control treatment. Ill denotes P <0.05 in student t-test for monotreatments vs. IgG1 control, # denotes P <0.05 in student t-tests for combination treatment groups vs. IgG1 controls and both constituent monotreatments. ( B ) Normalized IL-2 and IFN-γ expression in four promising combinations of TNF/TNFR inhibitors. ( C-D ) Proliferation in CD3 + cells during allogeneic one-way MLR measured at day 5 in the presence of combination pharmacological inhibition of TNF/TNFR targets of interest.* denotes P <0.05 in student t-test. Data from three unique stimulator-responder MLR pairs, mean ± SEM plotted. Large-molecule pharmacological TNF/TNFR inhibitors used: Adalimumab (abbr. Ada, α-TNF), Pateclizumab (α-LTA), Baminercept (abbr. Bam, LTβR decoy), Dapirolizumab (abbr. Dapiro, α-CD40L), Amlitelimab (abbr. Amlite, α-OX40L), CD30Li (α-CD30L), 4-1BB-Fc (4-1BB decoy), Quisovalimab (α-LIGHT), Duvakitug (α-TL1A), and GITRi (α-GITR).

    Journal: bioRxiv

    Article Title: Combination antagonism of TNF superfamily signaling for T cell immunosuppression

    doi: 10.64898/2026.04.27.721101

    Figure Lengend Snippet: ( A ) Interleukin-2 (IL-2) and interferon gamma (IFN-γ) inhibition in CD3 + cells during allogeneic one-way MLR measured at day 2 and day 5, respectively, treated with 50 nM combination pharmacological inhibitors of TNF/TNFR targets of interest. Monotreatment groups included 50 nM of human IgG1. Cytokine inhibition was calculated as percent reduction from IgG1 control treatment. Ill denotes P <0.05 in student t-test for monotreatments vs. IgG1 control, # denotes P <0.05 in student t-tests for combination treatment groups vs. IgG1 controls and both constituent monotreatments. ( B ) Normalized IL-2 and IFN-γ expression in four promising combinations of TNF/TNFR inhibitors. ( C-D ) Proliferation in CD3 + cells during allogeneic one-way MLR measured at day 5 in the presence of combination pharmacological inhibition of TNF/TNFR targets of interest.* denotes P <0.05 in student t-test. Data from three unique stimulator-responder MLR pairs, mean ± SEM plotted. Large-molecule pharmacological TNF/TNFR inhibitors used: Adalimumab (abbr. Ada, α-TNF), Pateclizumab (α-LTA), Baminercept (abbr. Bam, LTβR decoy), Dapirolizumab (abbr. Dapiro, α-CD40L), Amlitelimab (abbr. Amlite, α-OX40L), CD30Li (α-CD30L), 4-1BB-Fc (4-1BB decoy), Quisovalimab (α-LIGHT), Duvakitug (α-TL1A), and GITRi (α-GITR).

    Article Snippet: Adalimumab (Cat. HY-P9908), Pateclizumab (Cat. HY-P990034), Baminercept (Cat. HY-P99459), Amlitelimab (Cat. HY-P99434), Dapirolizumab (Cat. HY-P99842A), Quisovalimab (Cat. HY-P99810), Duvakitug (Cat. HY-P99842A), human IgG1 (Cat. HY-P99001) and human IgG4 (Cat. HY-P99003) were purchased from MedChemExpress.

    Techniques: Inhibition, Control, Expressing

    ( A-B ) Interleukin-2 (IL-2) and interferon gamma (IFN-γ) inhibition in CD3 + cells during allogeneic one-way MLR measured at day 2 and day 5, respectively, treated with 50 nM combination pharmacological inhibitors of TNF/TNFR targets of interest. Monotreatment groups included 50 nM of human IgG1. Cytokine expression normalized to IgG1 control treatment. * denotes P <0.05 in student t-test for monotreatments vs. IgG1 control. Data from three individual stimulator-responder MLR pairs, mean ± SEM plotted.

    Journal: bioRxiv

    Article Title: Combination antagonism of TNF superfamily signaling for T cell immunosuppression

    doi: 10.64898/2026.04.27.721101

    Figure Lengend Snippet: ( A-B ) Interleukin-2 (IL-2) and interferon gamma (IFN-γ) inhibition in CD3 + cells during allogeneic one-way MLR measured at day 2 and day 5, respectively, treated with 50 nM combination pharmacological inhibitors of TNF/TNFR targets of interest. Monotreatment groups included 50 nM of human IgG1. Cytokine expression normalized to IgG1 control treatment. * denotes P <0.05 in student t-test for monotreatments vs. IgG1 control. Data from three individual stimulator-responder MLR pairs, mean ± SEM plotted.

    Article Snippet: Adalimumab (Cat. HY-P9908), Pateclizumab (Cat. HY-P990034), Baminercept (Cat. HY-P99459), Amlitelimab (Cat. HY-P99434), Dapirolizumab (Cat. HY-P99842A), Quisovalimab (Cat. HY-P99810), Duvakitug (Cat. HY-P99842A), human IgG1 (Cat. HY-P99001) and human IgG4 (Cat. HY-P99003) were purchased from MedChemExpress.

    Techniques: Inhibition, Expressing, Control